Analytics Link Ecosystem
IQVIA Analytics Link Ecosystem establishes deep connections across our key data assets.
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology & Hematology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI®
-
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBlog
Delving Into Oncology Drug-Treated Patient Trends
Jul 10, 2025
Whilst we typically view the pharmaceutical industry through medicine sales and volume, patient-centred metrics are ultimately crucial for a fully comprehensive understanding of the market, including that of Oncology. IQVIA's new MIDAS Patient data estimates the number of patients taking medicines and can be segmented by cancer type, providing further granularity into Oncology dynamics. As cancer care becomes more personalised and multi-indicational, patient-level insights will be increasingly paramount to gain a comprehensive insight into the complexity of the oncology landscape.
Following our previous blog on disease area insights1, this blog investigates key trends and drivers in the number of oncology patients treated with prescription medicines across cancer types, using MIDAS Patient.
Together, breast cancer and prostate cancer represent 63% of all cancer-treated patients, as seen in Figure 1. This is largely due to these cancer types having high incidence rates, with breast cancer being the leading cancer for women, and prostate cancer second for men2. Additionally, these cancers are associated with widespread routine screening programmes and established treatment pathways, increasing the number of patients diagnosed and subsequently treated. As seen in the figure, these cancers are also among the lowest in terms of mortality rates. Consequently, with longer survival, a greater number of patients require chronic treatment, culminating in a higher overall number of treated patients.
Among the deadliest cancers are lung and colorectal cancers, with the combination of relatively high incidence and high mortality meaning they account for the highest absolute number of deaths3. The number of patients treated for lung cancer has grown relatively fast in the last five years, likely driven by therapeutic innovation for non-small cell lung cancer (NSCLC), the leading lung cancer subtype.
Many of the less common cancers have high mortality rates, indicating high unmet need. Of these, liver cancer had particularly fast growth in the number of treated patients, with a CAGR of 14% (2019-2024). This growth can partly be attributed to a rising number of new liver cancer cases and deaths, (which are predicted to increase by over 55% by 2040), and efforts to improve earlier liver cancer diagnosis4.
Another notable area of growth is haematological cancers, where drug-treated patient numbers grew with a 5-year CAGR of 8% compared to just 4% for solid cancers. This growth is likely driven by advances in targeted immunotherapies over the last 5 years, such as CAR-T cell therapy, antibody-drug conjugates, and bispecific antibodies5. These innovative next-generation biologics have effectively expanded the drug-treatable patient population for haematological cancers such as leukaemia and multiple myeloma.
These insights illustrate how estimated treated patient numbers can uncover key developments in medicines access, earlier diagnosis, and medical innovation.
For a deeper dive into these topics and beyond, watch our webinar on-demand now. Explore global market dynamics, treated patient trends in Oncology, Immunology, and Obesity, along with global health insights focusing on antibiotic use and resistance.
1 Revealing Pharma Trends Through Drug-Treated Patient Insights - IQVIA
2 Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality
3 World Health Organisation – Cancer Fact Sheet
4 International Agency for Research on Cancer - Press Release
5 Breaking New Ground: Advancing Cancer Care with Novel Therapeutic Modalities - IQVIA
Analyze market performance from sales to disease and patient
IQVIA MIDAS® has long been considered the industry benchmark for global market measurement, integrating the breadth and depth of IQVIA's unparalleled data assets with advanced analytics and deep domain expertise across 95 countries.
Just launched, MIDAS Patient adds patient insights across 600 diseases at scale to evolve with industry transformation towards multi-indication drugs and ensuring patient-centricity at the forefront. Life sciences organizations can now easily make disease comparisons supported by patient metrics across the MIDAS universe.
Related solutions
ChannelDynamics
Measure the performance of your sales force and marketing channels, adapt your commercial strategy and gain real world competitive insights.